CA2607965A1 - Systeme de culture pharmacocinetique presentant des barrieres biologiques - Google Patents
Systeme de culture pharmacocinetique presentant des barrieres biologiques Download PDFInfo
- Publication number
- CA2607965A1 CA2607965A1 CA002607965A CA2607965A CA2607965A1 CA 2607965 A1 CA2607965 A1 CA 2607965A1 CA 002607965 A CA002607965 A CA 002607965A CA 2607965 A CA2607965 A CA 2607965A CA 2607965 A1 CA2607965 A1 CA 2607965A1
- Authority
- CA
- Canada
- Prior art keywords
- microscale
- permeable material
- cells
- barrier
- permeable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004888 barrier function Effects 0.000 title claims description 106
- 210000004027 cell Anatomy 0.000 claims abstract description 446
- 239000000463 material Substances 0.000 claims abstract description 262
- 238000000034 method Methods 0.000 claims abstract description 183
- 239000012530 fluid Substances 0.000 claims abstract description 103
- 230000003993 interaction Effects 0.000 claims abstract description 95
- 210000003494 hepatocyte Anatomy 0.000 claims abstract description 58
- 210000000056 organ Anatomy 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 53
- 230000002496 gastric effect Effects 0.000 claims abstract description 52
- 229940079593 drug Drugs 0.000 claims abstract description 50
- 239000011230 binding agent Substances 0.000 claims abstract description 32
- 210000000941 bile Anatomy 0.000 claims abstract description 30
- 238000000338 in vitro Methods 0.000 claims abstract description 29
- 230000001413 cellular effect Effects 0.000 claims abstract description 26
- 230000002485 urinary effect Effects 0.000 claims abstract description 8
- 210000001519 tissue Anatomy 0.000 claims description 147
- 239000000126 substance Substances 0.000 claims description 96
- 239000007788 liquid Substances 0.000 claims description 66
- 239000008280 blood Substances 0.000 claims description 52
- 239000010410 layer Substances 0.000 claims description 52
- 229910052710 silicon Inorganic materials 0.000 claims description 49
- 239000010703 silicon Substances 0.000 claims description 49
- 210000004369 blood Anatomy 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 239000012528 membrane Substances 0.000 claims description 43
- 210000004379 membrane Anatomy 0.000 claims description 41
- 102000004169 proteins and genes Human genes 0.000 claims description 41
- 239000012620 biological material Substances 0.000 claims description 35
- 238000001727 in vivo Methods 0.000 claims description 33
- 230000009102 absorption Effects 0.000 claims description 30
- 238000010521 absorption reaction Methods 0.000 claims description 30
- 230000000694 effects Effects 0.000 claims description 26
- 230000004060 metabolic process Effects 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 23
- 210000002950 fibroblast Anatomy 0.000 claims description 21
- 230000003908 liver function Effects 0.000 claims description 20
- 239000012229 microporous material Substances 0.000 claims description 20
- -1 ZO-1 Proteins 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 18
- 239000002356 single layer Substances 0.000 claims description 18
- 238000009826 distribution Methods 0.000 claims description 17
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 16
- 238000013178 mathematical model Methods 0.000 claims description 16
- 108050007957 Cadherin Proteins 0.000 claims description 15
- 102000000905 Cadherin Human genes 0.000 claims description 15
- 210000001842 enterocyte Anatomy 0.000 claims description 15
- 239000011368 organic material Substances 0.000 claims description 15
- 108010035532 Collagen Proteins 0.000 claims description 14
- 102000008186 Collagen Human genes 0.000 claims description 14
- 229920001436 collagen Polymers 0.000 claims description 14
- 230000002503 metabolic effect Effects 0.000 claims description 14
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 230000008499 blood brain barrier function Effects 0.000 claims description 10
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 10
- 229910010272 inorganic material Inorganic materials 0.000 claims description 10
- 239000011147 inorganic material Substances 0.000 claims description 10
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 9
- 102000015735 Beta-catenin Human genes 0.000 claims description 9
- 108060000903 Beta-catenin Proteins 0.000 claims description 9
- 102000016289 Cell Adhesion Molecules Human genes 0.000 claims description 9
- 108010067225 Cell Adhesion Molecules Proteins 0.000 claims description 9
- 108090000304 Occludin Proteins 0.000 claims description 9
- 102000003940 Occludin Human genes 0.000 claims description 9
- 102000000591 Tight Junction Proteins Human genes 0.000 claims description 9
- 108010002321 Tight Junction Proteins Proteins 0.000 claims description 9
- 229940072056 alginate Drugs 0.000 claims description 9
- 229920000615 alginic acid Polymers 0.000 claims description 9
- 235000010443 alginic acid Nutrition 0.000 claims description 9
- 230000029142 excretion Effects 0.000 claims description 9
- 108010082117 matrigel Proteins 0.000 claims description 9
- 230000002685 pulmonary effect Effects 0.000 claims description 9
- 102000004162 Claudin-1 Human genes 0.000 claims description 8
- 108090000600 Claudin-1 Proteins 0.000 claims description 8
- 102100037260 Gap junction beta-1 protein Human genes 0.000 claims description 8
- 210000002867 adherens junction Anatomy 0.000 claims description 8
- 108010015416 connexin 32 Proteins 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 7
- 210000004324 lymphatic system Anatomy 0.000 claims description 6
- 230000032258 transport Effects 0.000 claims description 6
- 230000037365 barrier function of the epidermis Effects 0.000 claims description 5
- 230000001079 digestive effect Effects 0.000 claims description 5
- 230000003169 placental effect Effects 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 210000004400 mucous membrane Anatomy 0.000 claims description 4
- 239000000758 substrate Substances 0.000 abstract description 61
- 150000001875 compounds Chemical class 0.000 abstract description 51
- 230000017531 blood circulation Effects 0.000 abstract description 19
- 210000004556 brain Anatomy 0.000 abstract description 11
- 210000004185 liver Anatomy 0.000 description 89
- 238000004113 cell culture Methods 0.000 description 50
- 210000004072 lung Anatomy 0.000 description 49
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 45
- 239000001963 growth medium Substances 0.000 description 39
- 238000012360 testing method Methods 0.000 description 38
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 31
- 239000002609 medium Substances 0.000 description 28
- 229920002120 photoresistant polymer Polymers 0.000 description 28
- 238000003556 assay Methods 0.000 description 27
- 241001465754 Metazoa Species 0.000 description 25
- 230000006907 apoptotic process Effects 0.000 description 23
- 229960001674 tegafur Drugs 0.000 description 23
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 19
- 238000010586 diagram Methods 0.000 description 19
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 17
- 238000002474 experimental method Methods 0.000 description 17
- 229960002949 fluorouracil Drugs 0.000 description 17
- 230000006870 function Effects 0.000 description 16
- 230000004044 response Effects 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 15
- 238000004364 calculation method Methods 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 229910052759 nickel Inorganic materials 0.000 description 15
- 210000004789 organ system Anatomy 0.000 description 15
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 14
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 14
- 210000005265 lung cell Anatomy 0.000 description 14
- 230000037361 pathway Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- 229920001971 elastomer Polymers 0.000 description 13
- 230000012010 growth Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 13
- 239000011521 glass Substances 0.000 description 12
- 230000007246 mechanism Effects 0.000 description 12
- 230000003278 mimic effect Effects 0.000 description 12
- 230000030833 cell death Effects 0.000 description 11
- 239000000806 elastomer Substances 0.000 description 11
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 description 11
- 239000007789 gas Substances 0.000 description 11
- 239000002207 metabolite Substances 0.000 description 11
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 description 11
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 description 11
- 206010009944 Colon cancer Diseases 0.000 description 10
- 230000001276 controlling effect Effects 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 210000005229 liver cell Anatomy 0.000 description 10
- 208000029742 colonic neoplasm Diseases 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
- 229930182816 L-glutamine Natural products 0.000 description 8
- 238000010240 RT-PCR analysis Methods 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000010235 enterohepatic circulation Effects 0.000 description 8
- 238000012606 in vitro cell culture Methods 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 7
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 7
- 230000003833 cell viability Effects 0.000 description 7
- 230000004087 circulation Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000007613 environmental effect Effects 0.000 description 7
- 239000012091 fetal bovine serum Substances 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 238000007747 plating Methods 0.000 description 7
- 229920001296 polysiloxane Polymers 0.000 description 7
- 239000011148 porous material Substances 0.000 description 7
- 229920002379 silicone rubber Polymers 0.000 description 7
- 231100000027 toxicology Toxicity 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 239000004793 Polystyrene Substances 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 231100000433 cytotoxic Toxicity 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 238000005530 etching Methods 0.000 description 6
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
- 239000010931 gold Substances 0.000 description 6
- 229910052737 gold Inorganic materials 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 229920002223 polystyrene Polymers 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000007423 screening assay Methods 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010040476 FITC-annexin A5 Proteins 0.000 description 5
- 210000003445 biliary tract Anatomy 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 229940000406 drug candidate Drugs 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000002572 peristaltic effect Effects 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 230000003134 recirculating effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 229960000894 sulindac Drugs 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000002110 toxicologic effect Effects 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 4
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 4
- 238000000018 DNA microarray Methods 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 4
- 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000036983 biotransformation Effects 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 239000004926 polymethyl methacrylate Substances 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- 239000002699 waste material Substances 0.000 description 4
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000003833 bile salt Substances 0.000 description 3
- 231100000693 bioaccumulation Toxicity 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000004049 embossing Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000000099 in vitro assay Methods 0.000 description 3
- 210000001853 liver microsome Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 238000006213 oxygenation reaction Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 3
- 239000004417 polycarbonate Substances 0.000 description 3
- 229920000515 polycarbonate Polymers 0.000 description 3
- 229920000307 polymer substrate Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000820 replica moulding Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000004088 simulation Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000002723 toxicity assay Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- DQGMASZUGMDEFA-UHFFFAOYSA-N 1-methyl-2-nitrosoimidazole Chemical compound CN1C=CN=C1N=O DQGMASZUGMDEFA-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 102000018832 Cytochromes Human genes 0.000 description 2
- 108010052832 Cytochromes Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101710192343 NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 2
- 102100036777 NADPH:adrenodoxin oxidoreductase, mitochondrial Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010039918 Polylysine Proteins 0.000 description 2
- 101710104207 Probable NADPH:adrenodoxin oxidoreductase, mitochondrial Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 229910052581 Si3N4 Inorganic materials 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 210000000741 bile canaliculi Anatomy 0.000 description 2
- 229940093761 bile salts Drugs 0.000 description 2
- 239000003124 biologic agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 239000002575 chemical warfare agent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001010 compromised effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- 208000022602 disease susceptibility Diseases 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000009713 electroplating Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- GTSMOYLSFUBTMV-UHFFFAOYSA-N ethidium homodimer Chemical compound [H+].[H+].[Cl-].[Cl-].[Cl-].[Cl-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2C(C)=[N+]1CCCNCCNCCC[N+](C1=CC(N)=CC=C1C1=CC=C(N)C=C11)=C1C1=CC=CC=C1 GTSMOYLSFUBTMV-UHFFFAOYSA-N 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 238000009616 inductively coupled plasma Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001746 injection moulding Methods 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000000813 microcontact printing Methods 0.000 description 2
- 230000005486 microgravity Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000000206 photolithography Methods 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000656 polylysine Polymers 0.000 description 2
- 229910021426 porous silicon Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012913 prioritisation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 230000022814 xenobiotic metabolic process Effects 0.000 description 2
- XJZGNVBLVFOSKJ-XZULNKEGSA-N 5beta-cholestane-3alpha,7alpha,12alpha,26-tetrol Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(CO)C)[C@@]2(C)[C@@H](O)C1 XJZGNVBLVFOSKJ-XZULNKEGSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 102000008144 Cytochrome P-450 CYP1A2 Human genes 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 102100036194 Cytochrome P450 2A6 Human genes 0.000 description 1
- 101710101909 Cytochrome P450 2A6 Proteins 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010022528 Interactions Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 229920005479 Lucite® Polymers 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101000957678 Mus musculus Cytochrome P450 7B1 Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101150053185 P450 gene Proteins 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000644027 Perideridia lemmonii Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 229920001054 Poly(ethylene‐co‐vinyl acetate) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000957679 Rattus norvegicus 25-hydroxycholesterol 7-alpha-hydroxylase Proteins 0.000 description 1
- 241000719193 Seriola rivoliana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical class [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 210000002588 alveolar type II cell Anatomy 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940124977 antiviral medication Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000002113 chemopreventative effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 230000009073 conformational modification Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000609 electron-beam lithography Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000034964 establishment of cell polarity Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 231100000025 genetic toxicology Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003673 groundwater Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000000608 laser ablation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000010872 live dead assay kit Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- KERTUBUCQCSNJU-UHFFFAOYSA-L nickel(2+);disulfamate Chemical compound [Ni+2].NS([O-])(=O)=O.NS([O-])(=O)=O KERTUBUCQCSNJU-UHFFFAOYSA-L 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000001020 plasma etching Methods 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000012704 polymeric precursor Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 108700042419 rat CCA Proteins 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000004763 sulfides Chemical class 0.000 description 1
- 108010006247 sulfoxide reductase Proteins 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000000427 thin-film deposition Methods 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 238000003631 wet chemical etching Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/02—Form or structure of the vessel
- C12M23/16—Microfluidic devices; Capillary tubes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/44—Multiple separable units; Modules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Sustainable Development (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Clinical Laboratory Science (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68213105P | 2005-05-18 | 2005-05-18 | |
| US60/682,131 | 2005-05-18 | ||
| PCT/US2006/018951 WO2007021343A2 (fr) | 2005-05-18 | 2006-05-17 | Systeme de culture pharmacocinetique presentant des barrieres biologiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2607965A1 true CA2607965A1 (fr) | 2007-02-22 |
Family
ID=37758004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002607965A Abandoned CA2607965A1 (fr) | 2005-05-18 | 2006-05-17 | Systeme de culture pharmacocinetique presentant des barrieres biologiques |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1891201A4 (fr) |
| JP (1) | JP2008539787A (fr) |
| CN (1) | CN101223268A (fr) |
| CA (1) | CA2607965A1 (fr) |
| WO (1) | WO2007021343A2 (fr) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2302389B1 (fr) | 2002-05-09 | 2018-01-24 | The University of Chicago | Dispositif et procédé de transport et de réaction par bouchons entrainés par pression |
| US7901939B2 (en) | 2002-05-09 | 2011-03-08 | University Of Chicago | Method for performing crystallization and reactions in pressure-driven fluid plugs |
| GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
| GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
| US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
| US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
| US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
| JP2009536313A (ja) | 2006-01-11 | 2009-10-08 | レインダンス テクノロジーズ， インコーポレイテッド | ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法 |
| US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
| ATE540750T1 (de) | 2006-05-11 | 2012-01-15 | Raindance Technologies Inc | Mikrofluidische vorrichtung und verfahren |
| EP3536396B1 (fr) | 2006-08-07 | 2022-03-30 | The President and Fellows of Harvard College | Tensioactifs fluorocarbonés stabilisateurs d'émulsions |
| US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
| US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
| US9090885B2 (en) | 2007-07-26 | 2015-07-28 | The University Of Chicago | Co-incubating confined microbial communities |
| EP2200931B1 (fr) | 2007-09-19 | 2017-06-07 | The Charles Stark Draper Laboratory, Inc. | Structures microfluidiques pour applications biomédicales |
| CN101939644B (zh) * | 2008-01-10 | 2014-06-11 | 休雷尔公司 | 免疫系统模拟装置和方法 |
| US8622987B2 (en) | 2008-06-04 | 2014-01-07 | The University Of Chicago | Chemistrode, a plug-based microfluidic device and method for stimulation and sampling with high temporal, spatial, and chemical resolution |
| CN104328050B (zh) | 2008-07-16 | 2017-12-15 | 儿童医疗中心有限公司 | 具有微通道的器官模仿装置及其使用和制造方法 |
| EP2315629B1 (fr) | 2008-07-18 | 2021-12-15 | Bio-Rad Laboratories, Inc. | Bibliothèque de gouttelettes |
| US12038438B2 (en) | 2008-07-18 | 2024-07-16 | Bio-Rad Laboratories, Inc. | Enzyme quantification |
| EP3415235B1 (fr) | 2009-03-23 | 2025-11-12 | Bio-Rad Laboratories, Inc. | Manipulation de gouttelettes microfluidiques |
| US10196700B2 (en) | 2009-03-24 | 2019-02-05 | University Of Chicago | Multivolume devices, kits and related methods for quantification and detection of nucleic acids and other analytes |
| US9415392B2 (en) | 2009-03-24 | 2016-08-16 | The University Of Chicago | Slip chip device and methods |
| US9464319B2 (en) | 2009-03-24 | 2016-10-11 | California Institute Of Technology | Multivolume devices, kits and related methods for quantification of nucleic acids and other analytes |
| US9447461B2 (en) | 2009-03-24 | 2016-09-20 | California Institute Of Technology | Analysis devices, kits, and related methods for digital quantification of nucleic acids and other analytes |
| US8906644B2 (en) | 2009-08-26 | 2014-12-09 | The University Of Tokyo | Method for culture of hepatocytes |
| US20110082563A1 (en) * | 2009-10-05 | 2011-04-07 | The Charles Stark Draper Laboratory, Inc. | Microscale multiple-fluid-stream bioreactor for cell culture |
| WO2011042564A1 (fr) | 2009-10-09 | 2011-04-14 | Universite De Strasbourg | Nanomatériau marqué à base de silice à propriétés améliorées et ses utilisations |
| EP2517025B1 (fr) | 2009-12-23 | 2019-11-27 | Bio-Rad Laboratories, Inc. | Procédés pour réduire l'échange de molécules entre des gouttelettes |
| US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
| US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
| US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
| CA2789425C (fr) | 2010-02-12 | 2020-04-28 | Raindance Technologies, Inc. | Analyse numerique d'analyte comportant la correction d'erreur de polymerase |
| WO2012045012A2 (fr) | 2010-09-30 | 2012-04-05 | Raindance Technologies, Inc. | Dosages sandwich dans des gouttelettes |
| EP3859011A1 (fr) | 2011-02-11 | 2021-08-04 | Bio-Rad Laboratories, Inc. | Procédés permettant de former des gouttelettes mélangées |
| EP3736281A1 (fr) | 2011-02-18 | 2020-11-11 | Bio-Rad Laboratories, Inc. | Compositions et méthodes de marquage moléculaire |
| KR102117921B1 (ko) * | 2011-02-28 | 2020-06-03 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 세포 배양 시스템 |
| US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
| EP3709018A1 (fr) | 2011-06-02 | 2020-09-16 | Bio-Rad Laboratories, Inc. | Appareil microfluidique pour l'identification de composants d'une reaction chimique |
| US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
| US9725687B2 (en) | 2011-12-09 | 2017-08-08 | President And Fellows Of Harvard College | Integrated human organ-on-chip microphysiological systems |
| CN102643742B (zh) * | 2012-04-18 | 2013-06-05 | 西安建筑科技大学 | 一种自养菌动力学参数测量装置及测量方法 |
| US9528082B2 (en) | 2012-07-25 | 2016-12-27 | The Charles Stark Draper Laboratory, Inc. | Modular platform for multi-tissue integrated cell culture |
| US9249387B2 (en) | 2013-01-29 | 2016-02-02 | The Charles Stark Draper Laboratory, Inc. | Modular platform for multi-tissue integrated cell culture |
| US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
| US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
| US11193176B2 (en) | 2013-12-31 | 2021-12-07 | Bio-Rad Laboratories, Inc. | Method for detecting and quantifying latent retroviral RNA species |
| EP3254008B1 (fr) | 2015-02-04 | 2018-12-26 | The Charles Stark Draper Laboratory, Inc. | Soupape actionnée ou pompe pour dispositifs microfluidiques |
| KR20250042840A (ko) * | 2015-06-23 | 2025-03-27 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 세포 치료를 위해 세포 집단을 조건화하기 위한 방법 및 장치 |
| NL2015130B1 (en) * | 2015-07-09 | 2017-02-01 | Mimetas B V | Barrier function measurements. |
| US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
| CN105385598B (zh) * | 2015-11-30 | 2017-12-29 | 赵明光 | 人脑动静脉畸形生物力学模型及其体外构建方法 |
| CN105950461B (zh) * | 2016-07-20 | 2017-10-24 | 江苏瑞明生物科技有限公司 | 单细胞纳米精准给药系统 |
| WO2018071354A1 (fr) * | 2016-10-14 | 2018-04-19 | Wake Forest University Health Sciences | Appareil "corps-sur-puce" multi-organe utilisant un milieu commun |
| EP3639003A4 (fr) * | 2017-06-14 | 2021-03-17 | Emulate, Inc. | Effets de voyage dans l'espace sur des cellules cérébrales humaines |
| CA3074162A1 (fr) * | 2017-08-31 | 2019-03-07 | Philip Morris Products S.A. | Plaque de culture cellulaire, dispositifs et procedes d'exposition in vitro |
| DE102023209605B4 (de) | 2023-09-29 | 2025-06-12 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung eingetragener Verein | Vorrichtung, mikrofluidisches zirkulationssystem und verwendungen hiervon |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5043260A (en) * | 1987-11-02 | 1991-08-27 | Rhode Island Hospital | Perfusion device with hepatocytes |
| US6001585A (en) * | 1997-11-14 | 1999-12-14 | Cellex Biosciences, Inc. | Micro hollow fiber bioreactor |
| WO1999047922A2 (fr) * | 1998-03-18 | 1999-09-23 | Massachusetts Institute Of Technology | Ensemble de micro-tissus et de micro-organes vascularises et perfuses |
| US7288405B2 (en) * | 2001-04-25 | 2007-10-30 | Cornell Research Foundation, Inc. | Devices and methods for pharmacokinetic-based cell culture system |
| JP3853195B2 (ja) * | 2001-10-29 | 2006-12-06 | 株式会社ルネサステクノロジ | 半導体装置 |
| EP1499705A2 (fr) * | 2002-05-01 | 2005-01-26 | Massachusetts Institute of Technology | Microfermenteurs pour le criblage rapide et l'analyse de precessus biochimiques |
| JP4370082B2 (ja) * | 2002-08-26 | 2009-11-25 | 独立行政法人科学技術振興機構 | 神経細胞培養マイクロチャンバー |
| JP4118102B2 (ja) * | 2002-08-26 | 2008-07-16 | 独立行政法人科学技術振興機構 | 半透膜付き細胞培養マイクロチャンバー |
| JP4607432B2 (ja) * | 2003-05-12 | 2011-01-05 | 高木産業株式会社 | 細胞又は組織の培養装置 |
| US20050266393A1 (en) * | 2003-10-01 | 2005-12-01 | Baxter Gregory T | Circulating flow device for assays of cell cultures, cellular components and cell products |
-
2006
- 2006-05-17 JP JP2008512445A patent/JP2008539787A/ja active Pending
- 2006-05-17 WO PCT/US2006/018951 patent/WO2007021343A2/fr not_active Ceased
- 2006-05-17 CA CA002607965A patent/CA2607965A1/fr not_active Abandoned
- 2006-05-17 CN CN 200680025975 patent/CN101223268A/zh active Pending
- 2006-05-17 EP EP06813188A patent/EP1891201A4/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008539787A (ja) | 2008-11-20 |
| EP1891201A2 (fr) | 2008-02-27 |
| WO2007021343A3 (fr) | 2007-06-21 |
| EP1891201A4 (fr) | 2011-11-09 |
| CN101223268A (zh) | 2008-07-16 |
| WO2007021343A2 (fr) | 2007-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2445458C (fr) | Dispositifs et procedes pour systeme de culture cellulaire pharmacocinetique | |
| CA2607965A1 (fr) | Systeme de culture pharmacocinetique presentant des barrieres biologiques | |
| US20070048727A1 (en) | Biliary barrier | |
| US20070037277A1 (en) | Pharmacokinetic-based culture system with biological barriers | |
| AU2002359234A1 (en) | Devices and methods for pharmacokinetic-based cell culture system | |
| US20080064088A1 (en) | Devices and methods for pharmacokinetic-based cell culture system | |
| Kimura et al. | Organ/body-on-a-chip based on microfluidic technology for drug discovery | |
| Bhatia et al. | Microfluidic organs-on-chips | |
| US20050266393A1 (en) | Circulating flow device for assays of cell cultures, cellular components and cell products | |
| Yang et al. | Liver-on-a-chip: Considerations, advances, and beyond | |
| Nejati et al. | Cancer-on-chip: a breakthrough organ-on-a-chip technology in cancer cell modeling | |
| Busche et al. | HepaChip-MP–a twenty-four chamber microplate for a continuously perfused liver coculture model | |
| EP1820846A1 (fr) | Système de culture de cellules | |
| US20250034499A1 (en) | A microfluid device for simulating organ functions | |
| AU2007240203A1 (en) | Devices and methods for pharmacokinetic-based cell culture system | |
| Kim et al. | A novel multicellular organ-on-a-chip platform for high-throughput screening of urothelial responses | |
| Rajeshkannan et al. | Organ On A Chip |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |